present
studi
aim
investig
metabol
forsythosid
fta
human
fecal
bacteria
clarifi
relationship
intestin
metabol
pharmacolog
activ
fta
incub
human
fecal
microflora
vitro
investig
metabol
process
highli
sensit
specif
ultraperform
liquid
chromatographyquadrupol
timeofflight
mass
spectrometri
uplcqtofm
perform
use
softwar
metabolit
analysi
caffeic
acid
ca
hydroxytyrosol
ht
obtain
hydrolysi
fta
ca
hydrogen
form
acid
dca
anticomplementari
antimicrobi
antiendotoxin
activ
fta
metabolit
human
fecal
microflora
evalu
vitro
hemolysi
assay
agar
discdiffus
method
mic
valu
gel
clot
lal
assay
respect
metabolit
show
higher
biolog
activ
fta
especi
ht
dca
oral
administ
fta
may
metabol
ht
dca
pharmacolog
effect
fta
may
depend
intestin
bacteri
metabol
fructu
forsythia
fruit
forsythia
suspens
thunb
vahl
oleacea
wellknown
tradit
chines
medicin
tcm
wide
use
treatment
infect
acut
nephriti
pharyng
pyrexia
erysipela
ulcer
tonsil
gonorrhea
remark
fructu
forsythia
recommend
treatment
prevent
sever
acut
respiratori
syndrom
sar
may
caus
inappropri
activ
complement
system
hope
search
anticomplementari
compon
fructu
forsythia
main
bioactiv
compon
identifi
phenylethanoid
glycosid
lignan
flavonol
accord
phytochem
investig
forsythosid
fta
one
main
phenylethanoid
glycosid
fructu
forsythia
possess
strong
antimicrobi
antioxid
antivir
activ
chemic
structur
fta
compos
three
chemic
moieti
includ
aglycon
caffeic
acid
phenylethanoid
aglycon
hydroxytyrosol
sugar
moieti
content
approxim
total
much
higher
ingredi
absolut
oral
bioavail
approxim
significantli
lower
howev
fta
bioavail
demonstr
direct
relationship
pharmacolog
efficaci
forsythia
extract
repres
ingredi
lignan
phillyrin
accord
report
mechan
fta
intestin
absorpt
passiv
diffus
involv
fitoterapia
paracellular
transport
mainli
govern
tight
junction
fta
may
substrat
vitro
metabol
spraguedawley
rat
liver
microsom
moreov
herbal
medicin
oral
administ
activ
compon
therefor
brought
contact
intestin
microflora
alimentari
tract
mostli
compos
anaerob
transform
intestin
bacteria
absorpt
gastrointestin
tract
studi
herbal
compon
metabol
intestin
microflora
great
import
understand
biolog
effect
far
report
metabol
fta
intestin
bacteria
addit
studi
bioactiv
fta
focus
antibacteri
antiendotoxin
activ
anticomplementari
activ
studi
fta
anaerob
incub
human
fecal
microflora
metabolit
identifi
via
uplcqtofm
pharmacolog
effect
test
gener
anaerob
medium
broth
gam
broth
purchas
shanghai
kayon
biolog
technolog
co
ltd
shanghai
china
sheep
erythrocyt
rabbit
erythrocyt
antisheep
erythrocyt
antibodi
purchas
shanghai
fortun
biolog
technolog
co
ltd
shanghai
china
heparin
sodium
salt
iumg
purchas
china
nation
medicin
co
ltd
shanghai
china
normal
human
serum
obtain
healthi
adult
donor
guinea
pig
serum
obtain
healthi
guinea
pig
laboratori
anim
research
center
fudan
univers
escherichia
coli
staphylococcu
aureu
klebsiella
pneumonia
candida
albican
provid
laboratori
dr
mei
ge
forsythosid
purchas
shanghai
winherb
medic
technolog
co
ltd
hydroxytyrosol
caffeic
acid
acid
purchas
j
k
chemic
ltd
hplcgrade
acetonitril
methanol
purchas
merck
ultrapur
water
prepar
milliq
water
purif
system
millipor
chemic
reagent
analyt
grade
analys
perform
commerci
avail
acquiti
uplc
system
connect
onlin
acquiti
tqd
tripl
quadrupol
mass
spectromet
water
corp
milford
usa
condit
autosampl
data
collect
use
masslynx
softwar
separ
perform
syncroni
c
column
mm
id
thermo
usa
column
temperatur
set
mobil
phase
consist
ultrapur
water
contain
formic
acid
b
acetonitril
use
gradient
elut
b
min
b
min
b
min
b
min
b
min
b
min
flow
rate
mlmin
inject
volum
ms
instrument
consist
water
qtofm
water
corp
milford
usa
ioniz
perform
neg
electrospray
esi
mode
mass
rang
set
mz
da
scan
time
esi
sourc
oper
neg
ioniz
mode
capillari
voltag
kv
sourc
desolv
temperatur
set
respect
nitrogen
use
desolv
cone
ga
flow
rate
lh
respect
accur
mass
measur
data
centroid
acquisit
use
extern
refer
compris
solut
leucineenkephalin
purchas
j
k
chemic
ltd
infus
continu
esi
sourc
rate
via
syring
pump
data
process
use
softwar
water
corp
milford
usa
fresh
fecal
sampl
obtain
healthi
volunt
five
male
five
femal
year
age
gave
inform
written
consent
studi
protocol
volunt
histori
gastrointestin
disord
taken
antibiot
least
three
month
prior
studi
fresh
fecal
mixtur
sampl
immedi
homogen
time
gam
broth
sediment
remov
filtrat
three
piec
gauz
suspens
incub
anaerob
incub
air
replac
ga
mixtur
h
co
n
total
mg
fta
ad
human
fecal
suspens
ml
mixtur
incub
anaerob
incub
h
cultur
mixtur
remov
extract
water
satur
nbutanol
extract
evapor
residu
dissolv
methanol
ml
analyz
uplcqtofm
base
previou
describ
method
classic
altern
complement
pathwayinhibit
properti
fta
metabolit
investig
data
report
ch
ap
indic
concentr
result
inhibit
sheep
erythrocyt
concentr
result
rabbit
erythrocyt
hemolysi
inhibit
respect
heparin
sodium
salt
use
posit
control
antimicrobi
activ
assay
perform
fta
metabolit
five
test
bacteri
strain
three
replic
perform
sampl
posit
control
levofloxacin
bacteria
nystatin
dehydr
fungu
neg
control
steril
distil
water
antimicrobi
effect
sampl
assess
petri
dish
ml
nutrient
agar
plu
ml
microorgan
suspens
cfuml
od
nm
agar
solidifi
sampl
steril
distil
water
neg
control
ad
well
mm
diamet
plate
incub
h
inhibit
halo
evalu
mm
antimicrobi
effect
determin
measur
inhibit
halo
form
around
well
mic
valu
determin
dilut
method
accord
nation
committe
clinic
laboratori
standard
activ
sampl
posit
control
dissolv
dimethyl
sulfoxid
concentr
twofold
serial
dilut
solut
prepar
nutrient
broth
prepar
test
bacteria
strain
cfuml
od
nm
total
concentr
sampl
three
test
bacteri
strain
three
replic
well
perform
steril
roundbottom
plate
compar
sampl
noninocul
nutrient
broth
inocul
nutrient
broth
ml
sampl
ml
place
well
plate
incub
h
mic
valu
determin
lowest
concentr
inhibit
visibl
bacteri
growth
detect
unaid
eye
lal
assay
perform
duplic
use
commerci
lal
reagent
contain
clot
enzym
zhanjiang
c
biolog
ltd
guangdong
china
assay
perform
pyrogenfre
test
tube
ml
test
sampl
serial
dilut
ml
lal
reagent
ad
reaction
solut
mix
thoroughli
place
immedi
noncircul
water
bath
min
end
incub
period
test
tube
examin
presenc
stabl
solid
clot
gel
form
remain
intact
bottom
reaction
tube
invers
test
posit
test
consid
neg
gel
form
broke
collaps
invert
endotoxin
standard
e
coli
strain
euml
pyrogenfre
lal
reagent
water
provid
manufactur
use
control
fta
anaerob
incub
human
fecal
bacteri
mixtur
metabol
sampl
incub
h
extract
watersatur
nbutanol
analyz
uplcqtofm
demonstr
fig
total
three
peak
observ
compar
blank
sampl
contain
gam
standard
fta
solut
time
cours
determin
demonstr
fig
fta
convert
initi
time
h
increas
incub
tempor
variat
degrad
incub
h
convert
time
content
chang
exactli
opposit
indic
mutual
transform
two
metabolit
confirm
chemic
structur
three
metabolit
identifi
compar
retent
time
uv
spectra
refer
substanc
base
ms
data
data
summar
tabl
deglycosyl
hydrogen
metabolit
present
human
fecal
incub
base
result
fta
metabol
human
intestin
bacteria
propos
function
follow
fig
fta
first
desugar
form
ca
larg
amount
ht
ca
hydrogen
form
dca
effect
fta
metabolit
guinea
pig
complement
activ
classic
pathway
examin
dilut
guinea
pig
serum
heparin
sodium
use
posit
control
percent
activ
dilut
guinea
serum
occur
classic
pathway
complement
control
group
percentag
activ
dilut
normal
human
serum
occur
altern
pathway
complement
control
group
tabl
demonstr
fta
demonstr
anticomplementari
activ
either
classic
pathway
altern
pathway
ht
ca
dca
exhibit
complement
modul
properti
dosedepend
manner
ch
mgml
mgml
mgml
ht
dca
ca
respect
ap
assay
concentr
result
hemolysi
inhibit
rabbit
erythrocyt
mgml
ht
mgml
dca
mgml
ca
respect
ht
demonstr
signific
activ
compar
posit
inhibitor
heparin
sodium
ch
mgml
ap
mgml
primari
antimicrobi
screen
perform
use
agar
well
diffus
method
antimicrobi
activ
fta
metabolit
compar
levofloxacin
nystatin
dihydr
standard
antibiot
demonstr
tabl
none
test
sampl
exhibit
activ
c
albican
k
pneumonia
possess
inhibitori
activ
e
coli
aureu
ht
demonstr
inhibitori
effect
gramposit
bacteria
aureu
gramneg
bacteria
e
coli
fta
dca
limit
aureu
mic
valu
fta
ht
dca
bacteria
summar
tabl
ht
display
highest
antimicrobi
activ
overal
follow
fta
dca
antiendotoxin
effect
determin
gel
clot
lal
assay
vitro
result
present
tabl
fta
ca
invalid
even
maxim
concentr
howev
ht
dca
still
effect
dilut
four
three
time
respect
ht
possess
highest
antiendotoxin
effect
among
four
compound
fta
one
main
abund
activ
ingredi
fructu
forsythia
low
bioavail
mani
physiolog
factor
bile
intestin
microflora
gastrointestin
tract
ph
would
relat
drug
bioavail
accord
present
studi
oral
administr
fta
first
metabol
ca
ht
anaerob
condit
ca
convert
dca
human
fecal
bacteria
incub
process
well
activ
test
low
temperatur
due
fta
instabl
high
temperatur
fortun
metabolit
studi
found
figur
given
fta
incub
blank
contain
gam
accordingli
intestin
bacteri
metabol
play
import
role
gener
three
metabolit
fta
prove
deglycosyl
ca
ht
exist
glycosidas
intestin
microflora
metabol
behavior
observ
naringin
anthocyanin
metabol
hydrogen
also
play
import
role
ca
metabol
studi
result
differ
parkar
report
demonstr
ca
may
metabol
acid
dca
mainli
incub
h
human
fecal
bacteria
differ
may
due
differ
substrat
concentr
presenc
ht
metabol
process
far
report
anticomplementari
effect
fta
anticomplementari
activ
phenylethanoid
glycosid
monochasma
savatieri
previous
investig
present
studi
ht
main
human
intestin
bacteriaderiv
metabolit
fta
demonstr
consider
anticomplementari
activ
compar
posit
control
drug
heparin
sodium
first
time
ht
present
oliv
oil
mainli
secoiridoid
deriv
activ
polyphenol
oliv
tree
leav
oliv
pulp
oliv
oil
interestingli
previou
report
indic
extract
oliv
olea
europaea
l
oleacea
leav
demonstr
anticomplementari
activ
accordingli
ht
indispens
anticomplementari
effect
oliv
leav
convers
metabolit
ca
moder
effect
inhibit
classic
alter
pathway
complement
system
consist
previou
report
anticomplementari
effect
studi
compound
gnaphalium
affin
studi
fta
demonstr
inhibit
gramposit
bacteria
aureu
effect
gramneg
bacteria
e
coli
k
pneumonia
well
c
albican
result
indic
aureu
suscept
fta
among
four
strain
test
ht
possess
highest
antibacteri
activ
gramposit
bacteria
aureu
gramneg
bacteria
e
coli
result
consist
report
papadopoul
phenol
compound
also
demonstr
good
activ
aureu
oleuropein
dca
major
metabolit
antibacteri
effect
aureu
fta
support
phenylpropion
acid
activ
gramposit
bacteria
character
interact
antimicrobi
compound
target
site
also
need
studi
lal
assay
sensit
assay
current
known
endotoxin
three
type
lal
endotoxin
test
method
gelclot
method
chromogen
method
turbidimetr
method
approv
unit
state
pharmacopeia
evalu
endproduct
inject
drug
medic
devic
raw
materi
gelclot
method
thought
accur
sensit
procedur
determin
endotoxin
content
fewer
falseposit
falseneg
result
observ
method
use
studi
reveal
among
fta
intestin
bacteri
metabolit
ht
dca
antagonist
effect
endotoxin
dca
possibl
metabolit
ca
contain
odihydroxyl
structur
express
higher
antiendotoxin
anticomplementari
antibacteri
effect
ca
previou
result
suggest
olefin
doubl
bond
ca
import
factor
enhanc
antioxid
activ
thu
like
bond
ca
critic
pharmacodynam
express
dca
dca
reportedli
found
human
plasma
metabolit
ca
dietari
supplement
may
form
intestin
bacteria
wang
et
al
also
demonstr
ht
ca
identifi
two
major
metabolit
echinacosid
typic
phenylethanoid
glycosid
rat
urin
fece
sampl
anticomplementari
antiendotoxin
properti
ht
dca
determin
first
time
studi
therefor
dca
ht
consid
possibl
effect
metabolit
bodi
oral
administr
phenylethanoid
glycosid
fta
present
result
indic
biolog
activ
increas
fta
metabol
ht
dca
human
intestin
bacteria
coincid
previou
report
intestin
flora
play
import
role
metabol
oral
administ
bileexcret
compound
herbal
compon
transform
bioactiv
compound
intestin
bacteria
perform
pharmacolog
action
herbal
medicin
conclus
might
help
explain
fta
demonstr
posit
correl
dose
biolog
activ
forsythia
suspens
result
demonstr
presenc
intestin
bacteria
play
import
role
fta
metabol
oral
administr
metabol
process
involv
hydrolyt
reaction
gener
nonpolar
lowmolecularweight
byproduct
fta
accompani
activ
metabolit
result
indic
pharmacolog
effect
fta
may
depend
metabol
fta
intestin
bacteria
also
clarifi
low
fta
bioavail
howev
studi
perform
elucid
anticomplementari
antimicrobi
activ
vivo
well
mechan
action
relat
pharmacolog
activ
